# Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer

Source: https://onco.cc/trials/nct07367516/  
OnCo record `nct07367516` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TQB6411 in oesophageal cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer is a phase 1/2 interventional study registered as NCT07367516 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 105 participants planned, started 2026-02-12 and due to reach its primary completion in 2027-02. Interventions recorded: TQB6411 Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07367516
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial Evaluating the Safety and Efficacy of TQB6411 Injection in Participant s With Recurrent or Metastatic Esophageal Cancer Who Have Failed Prior PD-1/PD-L1 Inhibitor Plus Platinum-Based Chemotherapy
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 105

## Sources

- ClinicalTrials.gov NCT07367516: https://clinicaltrials.gov/study/NCT07367516

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [TQB6411](https://onco.cc/drugs/tqb6411/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct07367516.json